Effect on mortality and virological response of delaying antiretroviral therapy initiation in children receiving tuberculosis treatment

AIDS

Volumn 24, Issue 9, 2010, Pages 1341-1349

  Yotebieng, Marcel ^a   Van Rie, Annelies ^a   Moultrie, Harry ^b   Cole, Stephen R ^a   Adimora, Adaora ^c   Behets, Frieda ^a,c   Meyers, Tammy ^a,b  

^a IL   (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

ART initiation; Children; HIV; South Africa; Tuberculosis

Indexed keywords

EFAVIRENZ; ISONIAZID; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; PYRAZINAMIDE; RIFAMPICIN; STAVUDINE;

ADOLESCENT; ARTICLE; CHILD; CHILD CARE; DRUG RESPONSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; THERAPY DELAY; TUBERCULOSIS;

ADOLESCENT; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HUMANS; INFANT; MALE; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; SOUTH AFRICA; TIME FACTORS; TUBERCULOSIS, PULMONARY; VIRAL LOAD;

EID: 77952897265     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328339e576     Document Type: Article

References (35)

1. UNAIDS, AIDS epidemic update. 2009, Joint United Nations ProgrammeonHIV/AIDS (UNAIDS) Geneva, Switzerland.p.1-50.
2. Chakraborty R. HIV-1 infection in children: a clinical and immunologic overview. Curr HIV Res 2005; 3:31-41.
3. Newton SM, Brent AJ, Anderson S, Whittaker E, Kampmann B. Paediatric tuberculosis. Lancet Infect Dis 2008; 8:498-510.
4. Mukadi YD, Wiktor SZ, Coulibaly IM, CoulibalyD,Mbengue A, Folquet AM, et al. Impact of HIV infection on the development, clinical presentation, and outcome of tuberculosis among children in Abidjan, Cote d'Ivoire. AIDS 1997; 11:1151-1158.
5. Marais BJ, Graham SM, Cotton MF, Beyers N. Diagnostic and management challenges for childhood tuberculosis in the era of HIV. J Infect Dis 2007; 196 (Suppl 1):S76-S85.
6. Coovadia HM, Jeena P, Wilkinson D. Childhood human immunodeficiency virus and tuberculosis co-infections: reconciling conflicting data. Int J Tuberc Lung Dis 1998; 2:844-851.
7. Nelson LJ, Schneider E, Wells CD, Moore M. Epidemiology of childhood tuberculosis in the United States, 1993-2001: the need for continued vigilance. Pediatrics 2004; 114:333-341.
8. Nelson LJ, Wells CD. Global epidemiology of childhood tuberculosis. Int J Tuberc Lung Dis 2004; 8:636-647.
9. Elenga N, Kouakoussui KA, Bonard D, Fassinou P, Anaky MF, Wemin ML, et al. Diagnosed tuberculosis during the follow-up of a cohort of human immunodeficiency virus-infected children in Abidjan, Cote d'Ivoire: ANRS 1278 study. Pediatr Infect Dis J 2005; 24:1077-1082.
10. Palme IB, Gudetta B, Bruchfeld J, Muhe L, Giesecke J. Impact of human immunodeficiency virus 1 infection on clinical presentation, treatment outcome and survival in a cohort of Ethiopian children with tuberculosis. Pediatr Infect Dis J 2002; 21:1053-1061.
11. Kampmann B, Tena-Coki GN, Nicol MP, Levin M, Eley B. Reconstitution of antimycobacterial immune responses in HIV-infected children receiving HAART. AIDS 2006; 20: 1011-1018.
12. World Health Organization, Antiretroviral Therapy of HIV Infection in Infants and Children in Resource-Limited Settings: Towards Universal Access, W.H. Organization, Editor. 2006, World Health Organization: Geneva, Switzerland.
13. Mofenson LM, Oleske J, Serchuck L, Van Dyke R, Wilfert C. Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. MMWR Recomm Rep 2004; 53:1-92
14. South African National Tuberculosis Guidelines. 2008.
15. Department of Health. Operational Plan for Comprehensive HIV and AIDS Care, Management and Treatment for South Africa. 2003 19 November 2003 [cited 2009 April 2].
16. National Tuberculosis Control Programme Practical Guidelines, Health, Editor. 2000.
17. Meyers T, Eley B, Leoning W. Guidelines for the management of HIV-infected children-2005, Health, Editor. 2005, Jacana Media.
18. la Porte CJ, Colbers EP, Bertz R, Voncken DS, Wikstrom K, Boeree MJ, et al. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 2004; 48:1553-1560.
19. Ren Y, Nuttall JJ, Egbers C, Eley BS, Meyers TM, Smith PJ, et al. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr 2008; 47:566-569.
20. Centers for Disease Control and Prevention. A SAS program for CDC growth charts. http://www.cdc.gov/nccdphp/dnpa/growth charts/sas.htm. [Accessed 10 October 2007]
21. WHO Multicentre Growth Reference Study Group, WHO Child Growth Standards: Length/Height-for-Age, Weight-for-Age, Weight-for-Length, Weight-for-Height, and Body Mass Index-for-Age: Methods and Development., W. Press, Editor. 2006, WHO: Geneva, Switzerland.
22. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000; 11:561-570.
23. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11:550-560.
24. Hernan MA, Lanoy E, Costagliola D, Robins JM. Comparison of dynamic treatment regimes via inverse probability weighting. Basic Clin Pharmacol Toxicol 2006; 98:237-242.
25. Cole SR, Hernan MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol 2008; 168:656-664.
26. Lin DY, Wei LJ, Ying Z. Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika 1993; 80:557-572.
27. Lin DY, Wei LJ. The robust inference for the proportional hazards model. J Am Stat Assoc 1989; 84:1074-1078.
28. Velasco M, Castilla V, Sanz J, Gaspar G, Condes E, Barros C, et al. Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. J Acquir Immune Defic Syndr 2009; 50:148-152.
29. Zolopa A,AndersenJ,PowderlyW,SanchezA,Sanne I,Suckow C, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS ONE 2009; 4:e5575.
30. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008; 359:2233-2244.
31. Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21:335-341.
32. Manosuthi W, Kiertiburanakul S, Phoorisri T, Sungkanuparph S. Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. J Infect 2006; 53:357-363.
33. Torok ME, Yen NTB, Chau TTH, Mai NTH, Phu NH, et al. Randomised controlled trial of immediate versus deferred antiretroviral therapy in HIV-associated tuberculosis meningitis. in 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2009. San Francisco, California.
34. Gibb DM, Goodall RL, Giacomet V,McGeeL, Compagnucci A, Lyall H. Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial. Pediatr Infect Dis J 2003; 22:56-62.
35. Manosuthi W, Kiertiburanakul S, Sungkanuparph S, Ruxrung-tham K, Vibhagool A, Rattanasiri S, Thakkinstian A. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. AIDS 2006; 20:131-132.